evipedia.ai
← Back

High-Vitamin Butter Oil for Health & Longevity

Evidence Review created on 09/10/2026 using AI4L / Opus 5

Also known as: X-Factor Gold High Vitamin Butter Oil, Concentrated Butter Oil, Activator X Butter Oil, Centrifuged Butter Oil, HVBO

Motivation

High-vitamin butter oil is a concentrated fat fraction spun out of butter made from the milk of cows grazing on rapidly growing green grass. Removing water and milk solids leaves an oil that carries the fat-soluble portion of the milk — chiefly vitamin A, small amounts of vitamin D, and a form of vitamin K2 that is uncommon in plant foods.

Interest in the oil traces to the dentist Weston A. Price, who reported in the 1930s that butter from certain pastures contained an unidentified nutrient he named Activator X, and who fed it alongside cod liver oil to children with decayed teeth. The factor was later argued to be a form of vitamin K2, and a small supplement industry grew around reproducing his preparation for people who assemble diets deliberately around long-term health.

This review examines what is known and what is not: how the oil is made, what it plausibly delivers, what the evidence shows for its claimed effects on teeth, bone and arteries, what risks concentrated vitamin A carries, and how the claims about it are sourced and funded.

Benefits - Risks - Protocol - Conclusion

Background material giving a high-level view of high-vitamin butter oil and of the nutrient its reputation rests on.

  • On the Trail of the Elusive X-Factor: A Sixty-Two-Year-Old Mystery Finally Solved - Chris Masterjohn

    The primary modern argument that Price’s Activator X is menaquinone-4 (MK-4, the animal form of vitamin K2), read against his original data. Published by the Weston A. Price Foundation, whose sponsors sell the oil.

  • Vitamin K2: What It Does, Its Benefits, & Where to Find It - Chris Kresser

    A clinical overview of vitamin K2 covering MK-4 and menaquinone-7 (MK-7, the long-chain bacterial form), food sources and dosing — useful for judging what a butterfat concentrate can supply.

  • High Dose Vitamin K2 Builds New Bone - Michael Downey

    Summarises the Japanese prescription programme using 45 mg of MK-4 daily for bone density and fracture risk, showing the dose gap against food. Published by a supplement retailer selling MK-4.

  • Vitamin K2 Uses and Possible Side Effects - Stephen Rose

    A longevity-focused summary of what MK-4 and MK-7 do in bone, arteries, immunity and gut, and where the human evidence is thin — written by a non-commercial research nonprofit.

  • Differences between vitamin K1 and K2 - Rhonda Patrick

    Rhonda Patrick and Bruce Ames explain why menaquinone (vitamin K2) — the form butter oil supplies — activates matrix Gla protein and osteocalcin outside the liver, unlike plant-derived vitamin K1.

Content from two priority experts is not listed: a site search of peterattiamd.com for vitamin K2 returned no results at all, and hubermanlab.com yielded only passing mentions inside broader supplement segments; neither has published material on butter oil or on the concentrated MK-4 food form.

Grokipedia

Grokipedia has no article on high-vitamin butter oil. Its closest coverage is a page on a commercial blend of butter oil and fermented cod liver oil, treated there as distinct from the standalone concentrate.

Examine

Examine.com has no article on high-vitamin butter oil. Its closest coverage is a general food page on butter as a dietary fat, which does not discuss the centrifuged concentrate or the Activator X claim.

ConsumerLab

ConsumerLab has no product review, clinical update or answer covering high-vitamin butter oil. The product has never entered its independent testing programme, so no third-party potency or purity data exist there.

Systematic Reviews

Systematic reviews and meta-analyses (analyses that statistically pool separate studies) bearing on high-vitamin butter oil’s constituents — menaquinone-4 and preformed vitamin A — covering both the claimed benefits and the principal risk, since no systematic review examines the oil itself.

Mechanism of Action

High-vitamin butter oil is butterfat separated by centrifuge from butter, so its constituents are those of milk fat rather than a single active compound. Three matter most.

Menaquinone-4 (MK-4) acts as the cofactor for gamma-glutamyl carboxylase, the enzyme that attaches calcium-binding groups to a family of proteins called Gla proteins. Two are relevant: osteocalcin, which binds calcium into the bone matrix, and matrix Gla protein (MGP), which suppresses calcium deposition in artery walls. MK-4 also binds the steroid and xenobiotic receptor (SXR, a gene-regulating switch), altering bone gene transcription independently of carboxylation.

Retinol, the preformed form of vitamin A, converts to retinoic acid, which switches on genes governing epithelial renewal, immune cell maturation and tooth development.

Conjugated linoleic acid (CLA, a fatty acid formed by bacteria in the cow’s fermentation stomach) activates fat-metabolism regulators in adipose tissue.

Pharmacologically, MK-4 has a circulating half-life of one to two hours, travels on triglyceride-rich lipoproteins, concentrates in extrahepatic tissue rather than liver, and is cleared by side-chain shortening, a pathway Shearer and Newman review, with CYP4F2 (the liver enzyme that starts vitamin K breakdown). Retinyl esters, by contrast, are stored in the liver for months.

A competing reading is that dietary MK-4 is largely redundant: humans convert vitamin K1 and menadione (a synthetic vitamin K) into MK-4 in tissue through the enzyme UBIAD1, and food-level MK-4 doses do not raise blood MK-4 — so any effect may instead come from vitamin A, or from the fat matrix improving absorption of other nutrients.

Historical Context & Evolution

Butter oil was not developed as a supplement. Weston A. Price, a dentist and head of research for the American Dental Association, separated butterfat by centrifuge in the 1930s as a laboratory step, to measure a fat-soluble factor whose concentration rose sharply when cows grazed rapidly growing spring grass. He called it Activator X.

Price’s own reports, published in Nutrition and Physical Degeneration (1939), describe feeding the oil with high-vitamin cod liver oil to children in Cleveland with active tooth decay, and present dental radiographs he read as showing arrested cavities and new secondary dentine (fresh hard tissue laid down inside the tooth). He also tracked the factor with a colour reaction and with animal growth assays.

Those findings were never tested against a control group, the radiographs were interpreted by Price himself, and the children’s whole diet changed at the same time — so the observations remain unreplicated rather than refuted; no later group has repeated the protocol either to confirm or to overturn it.

Opinion has moved twice. In 2007 Chris Masterjohn, writing in the journal of the Weston A. Price Foundation — an advocacy organisation whose publication and conference revenue comes substantially from sponsors that sell the oil — argued Activator X was menaquinone-4, which gave the old work a molecular basis and drove commercial revival. Since then, evidence that food-level menaquinone-4 does not enter the bloodstream has weakened that identification, and it now stands as an inference rather than a demonstration.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no randomised trial has ever administered high-vitamin butter oil to people and measured a clinical endpoint, so the replicated-human-trial class of evidence this level requires does not exist for the oil.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single trial of the oil and no observational cohort that measured butter oil intake as an exposure, so both the single-trial class and the consistent-cohort class are empty.

Low 🟩

Reduced Activity of Tooth Decay

Price fed the oil with cod liver oil to children with active decay and reported arrested lesions and new dentine, but without controls or blinding. The nearest formal test, a systematic review of 24 old vitamin D trials, found roughly halved decay rates — a different nutrient entirely.

Magnitude: Direction is toward fewer active lesions, and it holds only in the conditions Price used — children with active decay, the oil paired with a vitamin A- and D-rich fish liver oil, alongside a wholesale diet change. The literature reports no outcome figure for butter oil itself.

Lower Coronary Heart Disease Mortality Associated with Dietary Menaquinone Intake

Butterfat is one of the few Western sources of menaquinones. In the Rotterdam Study, 4,807 adults showed lower coronary death and less aortic calcification with higher menaquinone intake; vitamin K1 showed nothing. The data are observational, and the menaquinone came mostly from cheese.

Magnitude: Relative risk 0.43 for coronary heart disease death in the highest versus the lowest third of menaquinone intake — relative risk being the risk in one group divided by the risk in another — with a 95% confidence interval of 0.24 to 0.77, meaning the true value most likely lies in that range.

Improved Lumbar Bone Mineral Density

MK-4 activates osteocalcin, so more calcium is bound into bone. A meta-analysis of 18 trials of prescription MK-4 found higher lumbar bone density and improved vitamin K activity markers, though fracture reduction was not statistically confirmed. Every trial used 45 mg daily, far above what a serving supplies.

Magnitude: Lumbar bone mineral density rose 0.05 g/cm² more than placebo (95% confidence interval 0.01 to 0.09) at 45 mg of MK-4 daily; the literature reports no outcome figure for the trace amount a butter oil serving delivers.

Improved Insulin Sensitivity ⚠️ Conflicted

MK-4 raises carboxylated osteocalcin, which signals to the pancreas and fat tissue. A placebo-controlled trial in healthy young men found improved insulin sensitivity after four weeks of MK-4; a meta-analysis of eight vitamin K trials found no effect. Net reading: an unreplicated single-trial signal.

Magnitude: Direction is toward improvement in the single trial, and it holds only at a pharmacological dose of 30 mg of MK-4 daily in healthy young men over four weeks. The pooled literature reports no outcome figure at any dose, and none at food-level intakes.

Conjugated Linoleic Acid Contribution to Fat Mass Reduction

Pasture butterfat carries more CLA than grain-fed butterfat. A 2023 meta-analysis of CLA with exercise found lower body fat; an earlier pooled analysis found reductions statistically significant but not clinically considerable. Both used multi-gram isolated doses at levels a serving cannot approach.

Magnitude: Body fat fell by a standardised mean difference of 0.42 (95% confidence interval 0.14 to 0.70) versus exercise alone — a standardised mean difference expressing the change as a fraction of the spread seen across the pooled trials — at isolated CLA intakes of roughly 3 g or more daily sustained over months. The literature reports no outcome figure for the CLA contained in a butter oil serving.

Speculative 🟨

Improved Arterial Elasticity Through Matrix Gla Protein Activation

Basis is mechanistic. MGP needs vitamin K to suppress arterial calcification, and a meta-analysis of vitamin K trials shows slower coronary calcium progression, but no controlled study has given butter oil or measured arterial stiffness.

Support for Craniofacial and Dental Arch Development

Basis is Price’s field observations of wide dental arches in populations eating fat-soluble-vitamin-rich foods. No controlled study has tested the oil, and no human outcome data on facial bone growth exist.

Benefit-Modifying Factors

  • VKORC1 and CYP4F2 variants: VKORC1 encodes the enzyme that recycles vitamin K; CYP4F2 encodes the enzyme that breaks it down. Carriers of the low-activity CYP4F2 variant retain more vitamin K per unit of intake, so a small food dose may go further.

  • BCO1 conversion status: BCO1 is the enzyme that splits plant carotene into retinol. Poor converters — a large minority — depend more on preformed retinol, so a concentrated animal source shifts vitamin A status more in them and matters less in efficient converters.

  • Baseline vitamin K activity markers: Benefit is plausible only where markers show a shortfall — high undercarboxylated osteocalcin (bone protein left unactivated when vitamin K is short) or high dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP, the inactive artery-protein form). Replete people have nothing to correct.

  • Baseline vitamin A and vitamin D status: Low serum retinol leaves room to gain; already-high retinol turns the same dose into a liability. Concurrent 25-hydroxyvitamin D (the storage form measured in blood) status matters because vitamin A and vitamin D compete at the same receptors.

  • Sex differences: Almost all MK-4 outcome data come from postmenopausal women, in whom bone turnover is high and vitamin K response is largest. Men have no comparable trial base, so any benefit inference for them is weaker.

  • Pre-existing conditions: Fat malabsorption from coeliac disease, cystic fibrosis, cholestasis (obstructed bile flow) or bariatric surgery blunts uptake of everything the oil carries. Chronic kidney disease raises dp-ucMGP markedly and is where vitamin K trials show the clearest marker response.

  • Age-related considerations: Undercarboxylated osteocalcin rises with age and dp-ucMGP rises steeply after 60, so older adults have the largest measurable shortfall to correct — and simultaneously the highest hip fracture risk from excess preformed vitamin A.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no controlled trial has administered high-vitamin butter oil and recorded adverse events, so the replicated-trial adverse-event class of evidence this level requires does not exist for this product.

Medium 🟥 🟥

Increased Hip Fracture Risk from Preformed Vitamin A

The best-documented downside of concentrating animal-source vitamin A. A meta-analysis of 13 cohort studies found higher hip fracture risk with high preformed vitamin A intake, and a Swedish cohort and nested case-control study found bone density fell and hip fracture risk doubled above 1.5 mg of retinol daily. Retinol appears to stimulate bone resorption (breakdown of bone tissue) and antagonise vitamin D. Because the current product label declares no vitamin A figure, the contribution of a serving cannot be calculated.

Magnitude: Relative risk 1.29 for hip fracture with high total vitamin A intake (95% confidence interval 1.07 to 1.57) and 1.23 for retinol specifically (1.02 to 1.48); risk roughly doubled above 1.5 mg of retinol daily compared with below 0.5 mg.

Congenital Malformations from Preformed Vitamin A in Pregnancy

Retinol crosses the placenta and, like the retinoid drugs derived from it, disrupts tissues formed from the cranial neural crest — face, skull, heart outflow and thymus. Evidence is a prospective cohort of 22,748 pregnancies, in which malformation prevalence rose above roughly 10,000 international units of preformed vitamin A daily. The exposure window is the first seven weeks, often before pregnancy is recognised, and because the label declares no vitamin A figure a serving cannot be counted against that ceiling.

Magnitude: Prevalence ratio 3.5 for cranial-neural-crest defects — a prevalence ratio being how many times more common a defect is in one group than in another — above 15,000 international units of preformed vitamin A daily from food and supplements versus 5,000 or less (95% confidence interval 1.7 to 7.3), and roughly 1 affected infant in 57 above 10,000 international units daily from supplements.

Low 🟥

Chronic Hypervitaminosis A

Vitamin A overload from sustained preformed intake causes liver injury, raised pressure inside the skull, dry skin, hair loss and bone pain. Evidence is uncontrolled human data: a review of vitamin A toxicity and a case series of 41 patients with liver damage. Stacking with cod liver oil raises risk.

Magnitude: Direction is toward liver injury as cumulative intake accumulates, and it holds at chronic intakes of roughly 25,000 to 50,000 international units (IU) daily sustained for months to years; single high intakes rarely cause it. The literature reports no outcome figure, because the evidence is selected case series with no exposed denominator from which a rate could be derived.

Elevated Low-Density Lipoprotein Cholesterol from Dairy Saturated Fat

Butterfat raises low-density lipoprotein (LDL) cholesterol relative to most other fats; a network meta-analysis of oils and solid fats placed butter near the top. The link here is dose-limited: a 2.5 mL serving supplies about 1.5 g of saturated fat, far below tested intakes.

Magnitude: In a network meta-analysis modelling a 10% isocaloric exchange (swapping one fat for another calorie for calorie), replacing butter with other oils lowered LDL cholesterol by 0.23 to 0.42 mmol/L. A 2.5 mL serving of the oil supplies about 1.5 g of saturated fat, far below the exchange amounts modelled.

Reduced Stability of Vitamin K Antagonist Anticoagulation ⚠️ Conflicted

Vitamin K opposes warfarin, so a concentrated source shifts clotting. A systematic review found the evidence conflicting: some studies show shorter clotting times, others show a minimum intake is needed for stable control, mainly above 150 micrograms daily. Net reading: abrupt intake changes destabilise control, not absolute amount.

Magnitude: Direction is toward reduced clotting time when intake rises sharply, and it holds mainly above roughly 150 micrograms of vitamin K daily. The literature reports no outcome figure for menaquinone-4 delivered in butterfat.

Speculative 🟨

Cholesterol Oxidation Products from Heat-Processed Butterfat

Basis is laboratory work on clarified butterfat, which has low oxidative stability and forms cholesterol oxidation products on heating. No human study has measured these after butter oil intake or linked them to any outcome.

Milk Protein Allergen Reactions

Basis is the product’s own allergen declaration, which states “Contains: Milk”. Centrifuged butterfat retains trace casein and whey, but no study has quantified residual protein in this product or reported reactions to it.

Risk-Modifying Factors

  • VKORC1 variants: VKORC1 encodes the enzyme recycling vitamin K and is the main determinant of warfarin dose. Carriers of high-sensitivity variants see larger swings in clotting time from a given change in vitamin K intake.

  • APOE4 carriage: APOE encodes the protein clearing fat-carrying lipoproteins from blood. The E4 variant slows clearance, prolonging exposure to fat-soluble vitamins delivered in a fat load and amplifying the LDL response to dairy fat.

  • Baseline biomarker levels: Raised liver enzymes, fasting retinyl esters (the stored vitamin A form, which spills into blood when liver stores overflow) above 10% of total vitamin A, or an unstable clotting ratio each turn this into a high-risk addition.

  • Sex-based differences: Preformed retinol is teratogenic (causes birth defects), so women who are pregnant or may become pregnant carry a risk men do not. Postmenopausal women also carry the highest baseline hip fracture risk that excess retinol compounds.

  • Pre-existing health conditions: Chronic liver disease concentrates the hypervitaminosis A risk, since the liver is both the storage site and the target organ. Cow’s milk protein allergy, hyperlipidaemia (high blood fats) and chronic kidney disease each shift the balance unfavourably.

  • Age-related considerations: Retinol clearance falls and liver stores rise with age, so the same intake produces higher tissue exposure after 65. Combined with age-related bone loss, this is where the fracture signal is concentrated.

Key Interactions & Contraindications

  • Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon): Caution, not absolute contraindication. Concentrated vitamin K can reduce the international normalised ratio (INR, a standard measure of how quickly blood clots), risking clot formation. Mitigation is a fixed daily amount plus INR checks weekly for one month.

  • Systemic retinoids (isotretinoin, acitretin, bexarotene): Absolute contraindication. Additive preformed vitamin A produces hypervitaminosis A with liver injury and raised intracranial pressure. No dose adjustment makes this safe; the oil is withheld for the duration of retinoid therapy.

  • Tetracycline antibiotics (doxycycline, minocycline): Caution. Both tetracyclines and excess vitamin A independently raise pressure inside the skull, and the combination has produced headache and visual disturbance. Mitigation is suspending the oil for the antibiotic course.

  • Lipase inhibitors (orlistat): Monitor. Orlistat blocks fat absorption and therefore blocks uptake of everything the oil carries, wasting the dose and risking deficiency. Mitigation is separating administration by at least two hours and monitoring fat-soluble vitamin status.

  • Bile acid sequestrants (cholestyramine, colesevelam, colestipol): Monitor. These bind fats in the gut and reduce absorption of vitamins A, D, E and K, risking deficiency. Mitigation is separating by four hours and rechecking serum retinol and 25-hydroxyvitamin D.

  • Over-the-counter vitamin A sources (cod liver oil, retinyl palmitate multivitamins, mineral oil laxatives): Caution. Cod liver oil and multivitamins add to the preformed vitamin A load, advancing hypervitaminosis A; mineral oil laxatives dissolve and carry away fat-soluble vitamins. Mitigation is totalling all sources daily.

  • Additive supplement interactions (MK-7, vitamin D3, calcium): Monitor. MK-7 and vitamin D3 act on the same Gla proteins and compound the intended effect, which is usually desirable but means the total dose must be counted once, not twice. Calcium is commonly paired with both.

  • High-dose vitamin E (above 800 IU daily): Caution. Alpha-tocopherol at that level antagonises vitamin K and can prolong clotting, cancelling the oil’s intended effect and adding bleeding risk in anticoagulated people. Mitigation is capping vitamin E at 400 IU.

  • Other intervention interactions: Monitor. Bariatric surgery, pancreatic enzyme insufficiency and very-low-fat diets all reduce delivery; ketogenic and high-fat diets increase it. Concurrent liver-loading interventions such as high-dose niacin warrant liver enzyme monitoring.

Populations who should avoid High-Vitamin Butter Oil:

  • Women who are pregnant, or planning pregnancy, where total preformed vitamin A would exceed 3,000 micrograms of retinol activity equivalents (RAE, the standard vitamin A unit) daily
  • People with documented cow’s milk protein allergy
  • People with chronic liver disease of Child-Pugh Class B or C (a liver-disease severity grade), or any cirrhosis
  • People taking systemic retinoids
  • People with established osteoporosis (bone density T-score of −2.5 or below, meaning bone density 2.5 standard deviations under a young adult average) whose habitual preformed retinol intake already exceeds 1.5 mg daily

Risk Mitigation Strategies

  • Total preformed vitamin A capped at 3,000 micrograms RAE daily: The cap counts the oil, cod liver oil, liver and any multivitamin together. It prevents the hip fracture and hypervitaminosis A risks, which are cumulative-intake driven.

  • No stacking with full-dose cod liver oil: The historical pairing doubles the retinol load. Halving each component, or alternating them on separate days, preserves the intended vitamin A and D synergy while avoiding chronic vitamin A overload.

  • Baseline and six-monthly liver enzymes plus serum retinol: Alanine aminotransferase and aspartate aminotransferase (ALT and AST, liver enzymes released when liver cells are damaged) plus fasting retinyl esters detect early hypervitaminosis A before symptoms appear.

  • A fixed daily amount before anticoagulation, with weekly clotting checks for one month: Stable intake, not low intake, is what protects INR control. This prevents the anticoagulation instability that abrupt vitamin K changes cause.

  • Refrigeration after opening, with the bottle discarded within three months: Butterfat oxidises once exposed to air and warmth. This limits exposure to the peroxidation products documented in heat-stressed clarified butterfat and preserves the fat-soluble vitamins.

  • Annual apolipoprotein B where more than one serving is taken daily: Apolipoprotein B (ApoB, one marker per cholesterol-carrying particle in blood) catches the LDL-raising effect of added dairy saturated fat before it accumulates unnoticed.

  • A batch certificate of analysis declaring retinol and menaquinone-4 content: Without declared amounts, neither the benefit nor the 3,000 microgram ceiling can be calculated, which is the single largest practical hazard this product presents.

Therapeutic Protocol

  • Standard manufacturer protocol: The dominant commercial product specifies half a teaspoon (2.5 mL) of liquid daily, or two capsules, supplying 25 calories and 2.5 g of fat, with 75 servings per 188 mL bottle.

  • Traditional-food approach: Practitioners in the Weston A. Price tradition pair the oil with fermented cod liver oil, reproducing Price’s original combination. That foundation and the dominant manufacturer sponsor each other, so this protocol’s promoters profit from it.

  • Isolated-nutrient approach: The competing route supplies MK-7 at 90 to 180 micrograms daily, or menatetrenone (the prescription name for MK-4) at 45 mg daily as used in Japanese osteoporosis practice, with retinol from liver or a declared-dose supplement.

  • Neither approach is established as the default: The food route offers an unmeasured dose in a natural matrix; the isolated route offers a measured dose with trial evidence behind it. No head-to-head comparison exists.

  • Best time of day: Taken with the largest fat-containing meal of the day, since absorption of every constituent depends on dietary fat and bile flow. No circadian advantage has been demonstrated for morning versus evening.

  • Half-life and dose splitting: MK-4’s one-to-two-hour circulating half-life argues for splitting the daily amount across two fat-containing meals rather than a single dose. Retinyl esters, stored for months, need no splitting.

  • Genetic polymorphisms influencing dose: VKORC1 and CYP4F2 status alters how far a given vitamin K dose goes; BCO1 poor-converter status raises the value of preformed retinol; APOE4 carriage prolongs exposure and argues for the lower end of any range.

  • Sex-based differences: Trial evidence for MK-4 comes almost entirely from postmenopausal women, so dosing precedent for men is extrapolated. Women of childbearing potential work to a lower ceiling because of retinol teratogenicity.

  • Age-related considerations: Adults over 65 have the largest vitamin K activity shortfall and the highest retinol-related fracture risk simultaneously, so protocols in this group favour the lowest serving with formal biomarker monitoring rather than open-ended use.

  • Baseline biomarkers guiding response: dp-ucMGP and undercarboxylated osteocalcin define whether a vitamin K shortfall exists at all; serum retinol and 25-hydroxyvitamin D define the headroom before the vitamin A ceiling is reached.

  • Pre-existing conditions influencing response: Fat malabsorption and cholestasis reduce delivery of everything in the oil; chronic kidney disease produces the largest dp-ucMGP shortfall and therefore the largest measurable marker response.

Discontinuation & Cycling

  • Not established as lifelong: Vitamin K effects reverse within weeks of stopping, while retinyl esters accumulate in the liver over months. That asymmetry argues for finite courses rather than indefinite use.

  • No withdrawal effects: No withdrawal syndrome has been described. Gla protein carboxylation reverts toward baseline over roughly two to four weeks, which is a return to prior state rather than a rebound.

  • Tapering not required: No pharmacological dependence exists, so abrupt cessation is uneventful — except in anticoagulated users, where stopping shifts clotting as much as starting does and warrants INR checks.

  • Seasonal cycling has a rationale: Price’s factor peaked in spring and early summer pasture, so seasonal use mirrors the natural exposure pattern. Some practitioners run three months on and one month off.

  • Cycling is not needed for efficacy: No tolerance or receptor downregulation has been shown for either constituent. Where cycling is used, the reason is limiting cumulative retinol, not maintaining response.

Sourcing and Quality

  • Effectively a single-producer market: Green Pasture Products supplies most of the world’s high-vitamin butter oil, sold as Concentrated Butter Oil (formerly X-Factor Gold). Concentration in one supplier means no competitive pressure toward independent verification.

  • The label declares no active content: The current Supplement Facts panel lists calories, fat, saturated fat and cholesterol only — no vitamin A, no vitamin K2, no CLA figure. The defining constituents are unquantified.

  • Cow diet and season drive content: Menaquinone and CLA content depend on rapidly growing green pasture, so batches vary with grass stage, weather and region. Products should state the grazing window and region for the batch.

  • What to look for: A batch certificate of analysis with declared retinol and menaquinone-4 figures, a peroxide value (a laboratory measure of fat rancidity), grass-fed certification, glass packaging, and a filling date rather than only an expiry date.

  • Oxidation is the main purity issue: Unrefined butterfat with no added antioxidant oxidises once opened. Refrigeration after opening, small container sizes and rapid turnover matter more here than for stabilised encapsulated supplements.

  • Independent testing has been contested: In 2015 a former Weston A. Price Foundation officer published testing claiming rancidity and low vitamin content in the manufacturer’s oils; the manufacturer and the foundation disputed it and she left. No neutral arbiter resolved it.

  • Cheaper adjacent options exist: Grass-fed ghee supplies the same butterfat matrix without the concentration claim; hard and blue cheeses supply substantially more total menaquinone per serving; natto supplies MK-7 at doses with trial evidence behind it.

Practical Considerations

  • Time to effect: Vitamin K activity markers shift within two to four weeks. Bone density changes, where measurable at all, took 6 to 24 months in the MK-4 trials. No timescale has been established for the oil itself.

  • Common pitfalls: Stacking the oil with cod liver oil and a multivitamin without totalling preformed vitamin A; leaving it unrefrigerated; assuming the food dose matches trial doses; and treating an undeclared label as equivalent to a declared one.

  • Regulatory status: In the United States the oil is a dietary supplement under the Dietary Supplement Health and Education Act, so no pre-market efficacy or potency review applies. Menatetrenone is a prescription drug in Japan and is not approved in the United States.

  • Cost and accessibility: Roughly $46 for a 188 mL bottle of 75 servings, about $0.61 per serving or $220 per year — several times the annual cost of an MK-7 supplement. Sold direct and through natural-food retailers.

  • Payer incentives shape the evidence: No insurer or health system reimburses the oil, so no institutional payer has an interest in funding trials of it. Conversely, Japanese reimbursement of menatetrenone funded most existing MK-4 outcome data, concentrating the evidence base in one country and indication.

Interaction with Foundational Habits

  • Sleep: No direct interaction. The plausible indirect route is competition between vitamin A and vitamin D at shared receptors, since vitamin D status tracks with sleep quality; excess preformed retinol could blunt that. No trial has measured sleep after vitamin K2 or butter oil, and no timing advantage relative to bedtime has been shown.

  • Nutrition: Potentiating in one direction. Absorption of every constituent requires dietary fat and bile, so the oil taken with a fat-containing meal delivers substantially more than the same dose fasted. Total preformed vitamin A must be counted across liver, cod liver oil and fortified foods, since the ceiling is a daily total, not per source.

  • Exercise: Indirect. Carboxylated osteocalcin, which MK-4 increases, is released during mechanical loading and signals to muscle and pancreas, so resistance training and the oil act on the same axis. Whether the combination outperforms training alone has not been tested; no blunting of adaptation has been reported, and no timing rule around workouts is established.

  • Stress management: No direct interaction. Neither menaquinone-4 nor retinol has a demonstrated effect on cortisol or the stress response in humans. The relevant indirect link runs the other way: chronic stress raises bone resorption, which is the process MK-4’s bone effects are proposed to oppose, so the two are complementary rather than interacting.

Monitoring Protocol & Defining Success

A baseline draw establishes where preformed vitamin A already sits and whether the liver can handle another concentrated source: serum retinol, fasting retinyl esters, a liver panel, a lipid panel with apolipoprotein B, and 25-hydroxyvitamin D. Anyone taking a vitamin K antagonist also has an international normalised ratio on file. Two vitamin K activity markers — undercarboxylated osteocalcin and dephosphorylated-uncarboxylated matrix Gla protein — are optional, and are the only way to tell whether the oil changes anything measurable.

Ongoing testing is light. Practitioners typically recheck the liver panel and serum retinol at three months, then every six to twelve months while use continues; lipids and 25-hydroxyvitamin D follow the same six-to-twelve-month rhythm. Anticoagulated users have the clotting ratio checked weekly for the first month, then return to their usual schedule.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum retinol 1.05–2.09 µmol/L Vitamin A status; the ceiling this product runs into Conventional labs flag only below 0.70 µmol/L. Poorly sensitive to liver overload — pair with retinyl esters
Fasting retinyl esters Below 10% of total circulating vitamin A Earliest signal that liver vitamin A stores are overflowing Requires a genuine 12-hour fast; a non-fasting sample is uninterpretable
Alanine aminotransferase (ALT) 10–26 U/L (men), 8–22 U/L (women) Detects the liver injury that chronic vitamin A excess causes Conventional upper limits reach 40–55 U/L, far above the functional target. Best paired with aspartate aminotransferase (AST)
Dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) Below 400 pmol/L Whether vitamin K is sufficient to keep the artery-protecting protein active Rises steeply with age and kidney disease. Non-fasting. The most responsive marker of vitamin K intake
Undercarboxylated osteocalcin Below 20% of total osteocalcin Whether vitamin K is sufficient for bone protein activation Fasting morning draw; osteocalcin has a marked daily rhythm and peaks overnight
25-hydroxyvitamin D 40–60 ng/mL Vitamin D status, which vitamin A competes with at shared receptors Conventional sufficiency starts at 30 ng/mL. Non-fasting; seasonal variation is large
Apolipoprotein B (ApoB) Below 80 mg/dL Whether added dairy saturated fat is raising cholesterol-carrying particle count Conventional laboratory reference intervals run to roughly 90–130 mg/dL, well above the functional target. Fasting preferred though not essential. More informative than LDL cholesterol alone at the same intake
International normalised ratio (INR) Within the individual’s prescribed target, commonly 2.0–3.0 Whether concentrated vitamin K is destabilising anticoagulation Only applicable to people on vitamin K antagonists. Weekly for the first month after any intake change

Qualitative markers worth tracking alongside the laboratory panel:

  • Dental sensitivity, and the dentist’s record of new or arrested lesions at routine six-monthly checks
  • Gum bleeding on brushing, which reflects both vitamin K status and gum health
  • Skin dryness, cracked lips and hair shedding — the earliest outward signs of vitamin A excess
  • Headache on waking or transient visual blurring, which signal raised pressure inside the skull
  • Energy and appetite, since early vitamin A overload presents as vague fatigue and loss of appetite before laboratory changes appear

Emerging Research

  • Direct test of menaquinone-4 absorption: The BioMicro crossover study at the University of Copenhagen (NCT07041645) gives 20 healthy adults carbon-13-labelled vitamin K1, MK-4, MK-7 and MK-9 in turn, tracking each in blood, urine and stool. Its stated hypothesis is that MK-4 will prove the least bioavailable of the four.

  • Cognitive endpoint for vitamin K: NutriCog at the Montreal Heart Institute (NCT06855953) enrols 40 adults with coronary heart disease and measures change in general cognitive function, processing speed, executive function and episodic memory — the first controlled attempt to attach a brain endpoint to vitamin K status.

  • Function rather than imaging in joints: A Tufts University trial (NCT05505552) in 37 adults with knee osteoarthritis uses plasma uncarboxylated matrix Gla protein as its primary endpoint, testing whether vitamin K repletion translates into lower-extremity function rather than radiographic change.

  • Vascular endpoint in a younger population: A trial in 160 adults with episodic migraine (NCT05943457) pairs monthly migraine days with arterial stiffness, one of the few vitamin K2 studies recruiting people who are otherwise healthy rather than elderly or dialysed.

  • Evidence that could weaken the case: Serum measurement already shows that 420 micrograms of MK-4 — far more than a serving supplies — left blood MK-4 undetectable in every participant in Sato et al., 2012, while MK-7 rose reliably. Replication would remove the mechanistic basis for concentrating MK-4 in food form at all.

  • Evidence that could strengthen the case: Systematic profiling of vitamin K forms in dairy fat by Fu et al., 2017 found total vitamin K tracks fat content, full-fat milk carrying roughly five times the amount in skimmed. Extending that method to centrifuged butter oil would quantify the exposure for the first time.

  • Unresolved dose-response on the risk side: Whether hip fracture risk from preformed vitamin A has a threshold below the amounts a daily serving supplies remains open after the Knapik & Hoedebecke, 2021 meta-analysis; no trial has been registered to test it, so the ceiling stays a cohort-derived estimate.

Conclusion

High-vitamin butter oil is a concentrated milk fat, spun out of butter from cows on fast-growing pasture, sold as a source of vitamin A, the animal form of vitamin K2, and small amounts of vitamin D.

The case for it rests almost entirely on inference. No trial has given the oil itself to people and measured an outcome. What exists is one dentist’s uncontrolled observations from the 1930s, later work on the isolated vitamin at far higher doses than a daily serving supplies, and population studies of vitamin K intake from foods other than butter. Each step in that chain is plausible; none of them has been closed. Working against it is evidence that the form of vitamin K2 in butter is poorly absorbed at food-sized doses, and that concentrated vitamin A tracks with weaker bones and more hip fractures over years.

The evidence base is also unusually narrow in who produced it. Almost all of the supporting literature originates from one advocacy foundation and one manufacturer that fund each other, and the current product label declares no vitamin A or vitamin K2 content at all, so even the exposure is unmeasured. No insurer or health system pays for the oil, so no institutional counterweight has funded independent testing either.

What remains is an interesting historical hypothesis with a real, quantifiable downside and no confirmed upside — a profile that lands differently for people who already assemble nutrient-dense diets and can obtain the same vitamin forms in declared amounts.

Top - Benefits - Risks - Protocol